| Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer (NCT06305702) | Liaoning Cancer Hospital & Institute | 2022-07-01 |
| Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer (NCT04778982) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2022-05-25 |
| A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases (NCT05042791) | Jiangxi Provincial Cancer Hospital | 2022-03-01 |
| ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) (NCT04829604) | Ambrx, Inc. | 2021-10-26 |
| Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity (NCT05036252) | Memorial Sloan Kettering Cancer Center | 2021-08-27 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases (NCT05018702) | Fudan University | 2021-07-14 |
| Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab (NCT05188495) | Peking University Cancer Hospital & Institute | 2021-05-10 |
| Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (NCT04681287) | Henan Cancer Hospital | 2021-04-23 |
| Testing a New Imaging Agent to Identify Cancer (NCT04692831) | Memorial Sloan Kettering Cancer Center | 2020-11-30 |
| A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC (NCT04398108) | Zai Lab (Shanghai) Co., Ltd. | 2020-08-25 |
| Feasibility of a New Technology for Isolating Circulating Tumour Cells (NCT03979339) | Centre Oscar Lambret | 2020-03-11 |
| A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer (NCT03691051) | Henan Cancer Hospital | 2018-11-20 |
| A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC. (NCT04385563) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2018-11-11 |
| Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC (NCT03417544) | Nancy Lin, MD | 2018-05-21 |
| Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (NCT03080805) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-03 |
| A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer (NCT02973737) | Jiangsu HengRui Medicine Co., Ltd. | 2016-07-20 |
| Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (NCT02605915) | Hoffmann-La Roche | 2015-12-31 |
| A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab (NCT02422199) | Jiangsu HengRui Medicine Co., Ltd. | 2015-05-01 |
| The Myocet/Lapatinib Study. ICORG 10-03, V5 (NCT01495884) | Cancer Trials Ireland | 2011-03-01 |